Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31058628 | 0.96 | ALDH1A1 (0.37) | ALDH1A1TSHRCAPN1CTSSCTSK | |
| SCHEMBL30918351 | 0.94 | ALDH1A1 (0.35) | ALDH1A1TSHRCAPN1CTSSCTSK | |
| SCHEMBL29400475 | 0.94 | ALDH1A1 (0.39) | ALDH1A1TSHRCAPN1CTSSCTSK | |
| SCHEMBL20561238 | 0.94 | ALDH1A1 (0.39) | ALDH1A1TSHRCAPN1CTSSCTSK | |
| SCHEMBL15407157 | 0.94 | ALDH1A1 (0.39) | ALDH1A1TSHRCAPN1CTSSCTSK | |
| SCHEMBL29401007 | 0.94 | ALDH1A1 (0.39) | ALDH1A1TSHRCAPN1CTSSCTSK | |
| SCHEMBL27429599 | 0.94 | ALDH1A1 (0.39) | ALDH1A1TSHRCAPN1CTSSCTSK | |
| SCHEMBL16893643 | 0.91 | ALDH1A1 (0.41) | ALDH1A1TSHRCAPN1F2PLG | |
| SCHEMBL27429597 | 0.91 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL31058627 | 0.90 | PLG (0.32) | ALDH1A1TSHRCAPN1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | ALDH1A1 4766/4885TSHR 1270/4885CAPN1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.